// App-Quantinova.ai

Mo1663 : ADALIMUMAB EFFICACY AND SAFETY BY DISEASE DURATION: ANALYSIS OF POOLED STUDIES OF Crohn's DISEASE

Researchers

Presenter

  • Paul Rutgeerts

Principal Investigators

  • William J. Sandborn

  • Stefan Schreiber

  • Jean Frederic Colombel

  • Sofie Berg

  • Jen-Fue Maa

  • Joel H. Petersson

  • Anne M. Robinson

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • University of California, San Francisco, San Francisco, California, United States

  • University of Calgary, Calgary, AB, Canada

  • University of Leuven, KUL, Leuven, Belgium

  • University Hospital Schleswig-Holstein, Lubeck, Germany

Locations

  • United States

  • Canada

  • Germany

  • Belgium

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Adalimumab

Outcome

  • Unknown

Study Design

  • open label

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved